Hypertension affects 80 million people in the United States. It remains poorly controlled, with only 54% of diagnosed patients treated to blood pressure targets. Hypertension management is complex in part due to the volume of antihypertensive agents, variable patient needs and responses, and inconsistent design and outcomes from clinical trials. Therefore, trustworthy clinical practice guidelines have a key role in hypertension management. The United States experienced a 10-year gap in publication of hypertension guidelines, followed by multiple guideline publications in 2013. These guidelines led to more controversy than clarity, as there was discordance among them. This review summarizes the guidelines and clinical statements influencing the current debate in order to facilitate appropriate application.
MozaffarianDBenjaminEJGoAS. Heart disease and stroke statistics – 2015: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322.
2.
HeidenreichPATrogdonJGKhavjouOA. Forecasting the future of cardiovascular disease in the United States: A Policy statement from the American Heart Association. Circulation. 2011;123(8):933–944.
3.
GoASBaumanMAKingSMC. An effective approach to high BP control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63(4):878–885.
4.
WeberMASchiffrinELWhiteWB. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15.
5.
Report of the joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237(3):255–261.
6.
ChobanianAVBakrisGLBlackHR. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP; National High BP Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP: the JNC 7 report. JAMA. 2003;289(19):2560–2572.
7.
ManciaGFagardRNarkiewicaK. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219.
8.
JamesPAOparilSCarterBL. 2014 Evidence-based guideline for the management of high BP in adults. JAMA. 2014;311(5):507–520.
9.
National Institute for Health and Clinical Excellence. Hypertension (CG127). Web site. http://www.nice.org.uk/guidance/cg127. Accessed October 2, 2014.
MesserliFH. Hypertension guidelines: political correctness trumping expertise?Hypertension. 2014;63(4):e81.
12.
JessupMHaroldJG. Response to Hypertension guidelines: Political correctness trumping expertise?Hypertension. 2014;63(4):e82.
13.
GibbonsGHHaroldJGJessupM. The next steps in developing clinical practice guidelines for prevention. Circulation. 2013;128(15):1716–1717.
14.
GibbonsGHShurinSBMensahGA. Refocusing the agenda on cardiovascular guidelines: An announcement from the National Heart, Lung, and Blood Institute. Circulation. 2013;128(15):1713–1715.
15.
HaroldJGJessupM. President’s Page: New ACC/AHA prevention guidelines: building a bridge to even stronger guideline collaborations. J Am Coll Cardiol. 2013;62(22):2145–2146.
WrightJTFineLJLacklandDT. Evidence supporting a systolic BP goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160(7):499–503.
AronowWSFlegJLPepineCJ. ACCF/AHA 2011 Expert consensus document on hypertension in the elderly. a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434–2506.
21.
BeckettNSPetersRFletcherAE; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
22.
PersellSD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076–1080.
23.
CalhounDJonesDTextorS. Resistant hypertension: diagnosis, evaluation, and treatment. a scientific statement from the American Heart Association Professional Education Committee of the council for high BP research. Hypertension. 2008;51(6):1403–1419.
24.
VáclavíkJSedlákRPlachýM. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–1075.
25.
ParthasarathyHKMénardJWhiteWB. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–990.
26.
HermidaRCAyalaDEMojónA. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010; 27(8):1629–1651.
27.
HermidaRCAyalaDEMojónA. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34(6):1270–1276.
28.
ArnettDKGoodmanRAHalperinJL. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. Circulation. 2014;130(18):1662–1667.
29.
FlackJMSicaDABakrisG. Management of high BP in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780–800.
30.
Kidney Disease; Improving Global Outcomes (KDIGO) BP Working Group. KDIGO clinical practice guideline for the management of BP in chronic kidney disease. Kidney Int Suppl. 2012;2:337–414.
31.
SmithSCJrBenjaminEJBonowRO. AHA/ACCF secondary prevention and risk factor reduction therapy for patients with coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473.
YancyCWJessupMBozkurtB. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol. 2013;62(16):e147–e239.
34.
American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2015;38(suppl 1):s49–s57.
35.
RipleyTLBrennerMFinksS. Key articles and guidelines in the management of hypertension: 2015 Update. J Pharm Pract. 2015;28(2):146–161. doi:10.1177/0897190014568382.
